Adjunctive Atorvastatin for Sepsis in the Acute Medical Unit: A Randomized Controlled Trial.

Area of Science:

• Critical Care Medicine
• Pharmacology
• Infectious Diseases

Background:

• Sepsis is a major global cause of mortality due to dysregulated host response to infection.
• Statins, like atorvastatin, possess anti-inflammatory and endothelial-stabilizing properties.
• Investigating atorvastatin's potential adjunctive role in sepsis management is crucial.

Purpose of the Study:

• To evaluate the efficacy of adjunctive atorvastatin in improving survival rates for sepsis patients.
• To assess atorvastatin's impact on organ support, hospitalization duration, and key inflammatory markers.

Main Methods:

• An open-label, randomized controlled trial was conducted with adult sepsis patients.
• Patients received either standard care plus atorvastatin 20mg or standard care alone.
• The primary endpoint was 28-day all-cause mortality; secondary endpoints included biomarker changes.

Main Results:

• A trend towards lower 28-day mortality was observed with atorvastatin (36% vs. 56%), but it was not statistically significant.
• No significant differences were found in organ support needs or hospital length of stay.
• Atorvastatin significantly reduced procalcitonin and lactate levels by day 7.

Conclusions:

• Adjunctive atorvastatin did not significantly reduce 28-day mortality in this sepsis cohort.
• Atorvastatin demonstrated a significant impact on reducing procalcitonin and lactate levels.
• These findings suggest atorvastatin may modulate sepsis-induced inflammatory and metabolic derangements.